重症监护干预在念珠菌血症与细菌血症危重患者中的应用:多中心回顾性队列研究
该多中心回顾性队列研究纳入德克萨斯州休斯顿8家医院2016至2023年ICU获得性血流感染患者1509例,其中念珠菌血症290例(19.2%),细菌血症1219例(80.8%),并用MIMIC-IV队列验证。念珠菌血症患者在培养时更常接受有创机械通气(72.8% vs 52.8%)、血管加压药(39.3% vs 24.0%)和连续肾脏替代治疗(15.2% vs 9.4%),感染发生更晚(7.2 vs 5.0天),30天死亡未调整OR为1.62(95%CI 1.25-2.09)。调整ICU干预和基线参数后,念珠菌血症与死亡率独立关联在主队列中未达统计学显著(OR 1.21;95%CI 0.92-1.60),但在MIMIC-IV队列中显著(OR 1.48;95%CI 1.003-2.17)。作者认为,对需要高资源ICU治疗的患者启动经验性抗生素时,应考虑经验性抗真菌治疗。
要点
- 在1509例ICU血流感染患者中,念珠菌血症占19.2%(290例),细菌血症占80.8%(1219例)。
- 念珠菌血症患者在培养时更常接受有创机械通气(72.8% vs 52.8%)、血管加压药(39.3% vs 24.0%)、连续肾脏替代治疗(15.2% vs 9.4%)。
- 念珠菌血症感染发生晚于细菌血症(7.2 vs 5.0天),30天死亡未调整OR为1.62(95%CI 1.25-2.09)。
- 调整ICU干预和基线参数后,念珠菌血症与死亡率独立关联在主队列未达统计学显著(OR 1.21;95%CI 0.92-1.60),MIMIC-IV队列显著(OR 1.48;95%CI 1.003-2.17)。
- 作者认为,对需要高资源ICU治疗的患者启动经验性抗生素时,应考虑经验性抗真菌治疗。
适用人群与场景
- 来自德克萨斯州休斯顿8家医院系统的ICU患者,2016至2023年发生血流感染(念珠菌血症或细菌血症)。
- 验证队列为MIMIC-IV数据库中ICU血流感染患者。
处置流程与药物剂量
- 作者认为,对需要高资源ICU治疗(有创机械通气、血管加压药、连续肾脏替代治疗)的患者启动经验性抗生素时,应考虑经验性抗真菌治疗。
研究设计与关键结果
- 多中心回顾性队列研究,主队列1509例,念珠菌血症290例(19.2%),细菌血症1219例(80.8%)。
- 念珠菌血症组 vs 细菌血症组:有创机械通气72.8% vs 52.8%(p<0.001),血管加压药39.3% vs 24.0%(p<0.001),连续肾脏替代治疗15.2% vs 9.4%(p=0.006)。
- 念珠菌血症感染发生时间晚于细菌血症(7.2 vs 5.0天;p<0.001)。
- 念珠菌血症组30天死亡未调整OR为1.62(95%CI 1.25-2.09)。
- 调整ICU干预和基线参数后,主队列念珠菌血症与死亡率OR为1.21(95%CI 0.92-1.60),未达统计学显著;MIMIC-IV队列OR为1.48(95%CI 1.003-2.17)。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究,并通过MIMIC-IV队列验证。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对需要高资源ICU治疗(有创机械通气、血管加压药、连续肾脏替代治疗)的患者启动经验性抗生素时,应考虑经验性抗真菌治疗。
- 原文未据此给出其他推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Candida species are one of the most common causes of ICU-onset bloodstream infection (BSI). Yet, there is no robust guidance on when to initiate empiric antifungals for ICU patients suspected of BSI. We compared patients with ICU-onset candidemia vs. ICU-onset bacteremia to determine which patients may benefit from empiric antifungals.
DESIGN: We compared characteristics between patients with bacteremia vs. candidemia at time of culture. We determined risk factors for death and constructed a multivariable regression to determine if candidemia is an independent risk factor for death.
SETTING/PATIENTS: We included ICU patients from a hospital system in Houston, Texas (n = 8 hospitals) with a BSI from 2016 to 2023 and validated our findings using ICU patients with a BSI in the publicly available Medical Information Mart for Intensive Care (MIMIC)-IV cohort.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Of 1509 total patients in our primary cohort, 290 (19.2%) had candidemia and 1219 (80.8%) had bacteremia. Patients with candidemia were more likely to be on invasive mechanical ventilation (72.8% vs. 52.8%; p < 0.001), vasopressors (39.3% vs. 24.0%; p < 0.001), and continuous renal replacement therapy (15.2% vs. 9.4%; p = 0.006) at the time of culture. They contracted infection later in ICU stay than bacteremia patients (7.2 vs. 5.0 d; p < 0.001) and were more likely to die within 30 days of culture (unadjusted odds ratio [OR], 1.62; 95% CI, 1.25-2.09). After adjusting for ICU interventions (invasive mechanical ventilation, vasopressors, and continuous renal replacement therapy) and baseline parameters, candidemia was not independently associated with mortality compared with bacteremia in our primary cohort (OR, 1.21; 95% CI, 0.92-1.60) but was in the MIMIC-IV cohort (OR, 1.48; 95% CI, 1.003-2.17).
CONCLUSIONS: Patients with significant ICU resource utilization are at increased risk for candidemia. Our data suggest that when initiating empiric antibiotics in patients requiring high-resource ICU care, empiric antifungal therapy should be considered.
参考来源
- Jones MN, Nigo M, Casarin S, et al. Utilization of Intensive Care Interventions in Critically Ill Patients With Candidemia Versus Bacteremia: A Multicenter Retrospective Cohort Study. Crit Care Med. 2025. PMID: 41631939. doi:10.1097/CCM.0000000000006963
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。